Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in recurrent small cell lung cancer
NCT03732846Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in small cell lung cancer (SCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 18 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03732846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732846.